• Alvar J, Vélez ID, Bern C et al.; WHO Leishmaniasis Control Team 2012 Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7, e35671. doi: 10.1371/journal.pone.0035671. Epub 2012 May 31.
  • Bhattacharya SK, Sur D, Sinha PK & Karbwang J (2006) Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible and operationally achievable. Indian Journal of Medical Research 123, 195196.
  • Boelaert M, Meheus F, Sanchez A et al. (2009) The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Tropical Medicine and International Health 14, 639644.
  • Chemtob D, Epstein L, Slater PE & Weiler-Ravell D (2001) Epidemiological analysis of tuberculosis treatment outcome as a tool for changing TB control policy in Israel. The Israel Medical Association Journal 3, 479483.
  • Croft SL, Sundar S & Fairlamb AH (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews 19, 111126.
  • Hasker E, Singh SP, Malaviya P et al. (2010) Management of visceral leishmaniasis in rural primary health care services in Bihar, India. Tropical Medicine and International Health 15, 5562.
  • Joshi AB, Banjara MR, Pokhrel S, Jimba M, Singhasivanon P & Ashford RW (2006) Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities. Kathmandu University Medical Journal 4, 488496.
  • Khader A, Farajallah L, Shahin Y et al. (2012a) Cohort monitoring of persons with diabetes mellitus in a primary healthcare clinic for Palestine refugees in Jordan. Tropical Medicine and International Health 17, 15691576.
  • Khader A, Farajallah L, Shahin Y et al. (2012b) Cohort monitoring of persons with hypertension: an illustrated example from a primary healthcare clinic for Palestine refugees in Jordan. Tropical Medicine and International Health 17, 11631170.
  • Lowrance D, Filler S, Makombe S et al. (2007) Assessment of a national monitoring and evaluation system for rapid expansion of antiretroviral treatment in Malawi. Tropical Medicine and International Health 12, 377381.
  • Maher D 2012 The power of health information– the use of cohort monitoring in managing patients with chronic non-communicable diseases. Tropical Medicine and International Health 17, 15671568.
  • Malaviya P, Singh RP, Singh SP et al. (2011) Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys versus a health service-based reporting system. Tropical Medicine and International Health 16, 11591166.
  • Malaviya P, Hasker E, Singh RP, Van Geertruyden JP, Boelaert M & Sundar S (2013) Village health workers in Bihar, India: an untapped resource in the struggle against kala-azar. Tropical Medicine and International Health 18, 188193.
  • Mondal D, Singh SP, Kumar N, et al. (2009) Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Neglected Tropical Diseases 3, e355. doi:10.1371/journal.pntd.0000355.
  • Ormerod LP, Horsfield N & Green RM (2002) Tuberculosis treatment outcome monitoring: Blackburn 1996–2000. Journal of Infection 45, 8889.
  • Rijal S, Ostyn B, Uranw S et al. (2013) Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, re-infection or non-compliance. Clinical Infectious Diseases [Epub ahead of print].
  • Singh SP, Hirve S, Huda MM et al. (2011) Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Neglected Tropical Diseases 5, e960. doi:10.1371/journal.pntd.0000960.
  • Sundar S, Jha TK, Thakur CP et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347, 17391746.
  • Sundar S, Singh A, Rai M et al. (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clinical Infectious Diseases 55, 543550.
  • TDR/World Health Organization 2010 Indicators for monitoring and evaluation of the kala-azar elimination programme. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases.
  • UNRWA Health Department (2009) Technical Instructions and Management Protocols on Prevention and Control of Non-Communicable Diseases. Technical Instruction Series: Number HD⁄DC⁄ 01 ⁄ 1997. Revision No.4 – June 2009
  • Veen J, Raviglione M, Rieder HL et al. (1998) Standardized tuberculosis treatment outcome monitoring in Europe. European Respiratory Journal 12, 505510.
  • Volmink J & Garner P (2007) WITHDRAWN: interventions for promoting adherence to tuberculosis management. Cochrane Database Systematic Review 18, CD000010.
  • World Health Organization; International Union Against Tuberculosis and Lung Disease; Royal Netherlands Tuberculosis Association 2001 Revised international definitions in tuberculosis control. The International Journal of Tuberculosis and Lung Disease 5, 213215.
  • World Health Organization 2003 Global Tuberculosis Control. Surveillance, Planning, Financing. WHO Report 2003. Document WHO/CDS/TB/2003.316. World Health Organization, Geneva.
  • World Health Organization (2005) Regional office for South-East Asia. Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005-2015)[document on the internet]. WHO SEARO, New Delhi. Available from: (accessed 29 June 2012).
  • World Health Organization 2006 Revised TB recording and reporting forms and registers – version 2006 WHO/HTM/TB/2006.373 available on http// (accessed 1 December 2012).